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ABSTRACT
Δ9-Tetrahydrocannabinol, the main psychoactive component of cannabis, exerts its central effects through activation
of the cerebral type 1 cannabinoid (CB1) receptor. Pre-clinical studies have provided evidence that chronic cannabis
exposure is linked to decreased CB1 receptor expression and this is thought to be a component underlying drug
tolerance and dependence. In this study, we make first use of the selective high-affinity positron emission tomography
(PET) ligand [18F]MK-9470 to obtain in vivomeasurements of cerebral CB1 receptor availability in 10 chronic cannabis
users (age = 26.0 ± 4.1 years). Each patient underwent [18F]MK-9470 PET within the first week following the last
cannabis consumption. A population of 10 age-matched healthy subjects (age = 23.0 ± 2.9 years) was used as control
group. Parametric modified standardized uptake value images, reflecting CB1 receptor availability, were calculated.
Statistical parametric mapping and volume-of-interest (VOI) analyses of CB1 receptor availability were performed.
Compared with controls, cannabis users showed a global decrease in CB1 receptor availability (−11.7 percent). VOI-
based analysis demonstrated that the CB1 receptor decrease was significant in the temporal lobe (−12.7 percent),
anterior (−12.6 percent) and posterior cingulate cortex (−13.5 percent) and nucleus accumbens (−11.2 percent).
Voxel-based analysis confirmed this decrease and regional pattern in CB1 receptor availability in cannabis users. These
findings revealed that chronic cannabis use may alter specific regional CB1 receptor expression through neuroadaptive
changes in CB1 receptor availability, opening the way for the examination of specific CB1-cannabis addiction interac-
tions which may predict future cannabis-related treatment outcome.
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INTRODUCTION
Cannabis is the most commonly produced and consumed
illicit drugworldwide. According to the 2013World Drug
Report, the annual cannabis consumption is estimated to
be 3.9 percent of the world’s population (i.e. 180.6
million of users) aged 15–64 years (United Nations
Office on Drugs and Crime (UNODC) 2013). An estimated
10 percent of cannabis users are dependent, and relapse
rates for cannabis users in treatment are comparable
with those found for other drugs of abuse (Weinstein &
Gorelick 2011). Clinical and laboratory studies demon-
strated that chronic cannabis smokers can experience
withdrawal symptoms upon cessation of cannabis
smoking (i.e. insomnia, cognitive impairment, emotional
liability, psychiatric depression, irritability and anger)
and have difficulty abstaining from cannabis use (Cooper
& Haney 2008). Moreover, there is growing evidence
that intensive exposure to cannabis increases the risk of
adverse health effects, such as impaired respiratory and
cardiovascular function, psychotic disorders and a
dependence syndrome (Henquet et al. 2008; Hall &
Degenhardt 2009). However, our knowledge of the
effects of long-term cannabis use on the brain remains
relatively poor. Therefore, enhanced understanding of
the effects of chronic cannabis use on the disruption of
interneuronal signalling and information processing
may quantify the extent of the risks of long-term use, and
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may open the way to novel interventions targeting medi-
ating mechanisms (Murray et al. 2007).
Discovery of the endocannabinoid system, comprising
endogenous cannabinoids and cannabinoid receptors
(Wilson & Nicoll 2002), has prompted interest in under-
standing the neurobiological effects of chronic cannabis
use. The primary psychoactive component of cannabis,
Δ9-tetrahydrocannabinol (Δ9-THC) (Mechoulam 1970),
exerts its known central effects through the activation of
the type 1 cannabinoid (CB1) receptor (Glass, Dragunow
& Faull 1997; Iversen 2003). In rodents and humans,
CB1 receptors are highly concentrated in the basal gan-
glia, hippocampus, cingulate cortex, cerebellum and
neocortex (Glass et al. 1997), consistent with the major
psychological and motor effects of Δ9-THC (Murray et al.
2007). The major mechanism of CB1 receptor action is
an inhibiting modulation of synaptic transmission, by
presynaptic action on the release of other neurotransmit-
ters, mainly glutamate, gamma-amino butyric acid and
dopamine (Wilson & Nicoll 2002; Hoffman & Lupica
2013), the crucial neurotransmitter for reinforcing
and rewarding effects of drugs of abuse. CB1 receptor
expression in the mesocorticolimbic pathway seems to
contribute to the rewarding and reinforcing effects of
cannabinoids (Cooper & Haney 2008). CB1-receptor-
agonist-induced conditioned place preference and
conditioned place aversion are both blocked by adminis-
tration of CB1 receptor inverse agonist SR141716A
(Braida et al. 2004), demonstrating that reward-related
effects are mediated by the CB1 receptor. Administration
of SR141716A has also shown to antagonize the positive
reinforcing effects of cannabis (Zangen et al. 2006). In
humans, subjective effects of cannabis such as ‘good drug
effect’, ‘high’ and ‘liking’ are also mediated through the
CB1 receptor (Huestis et al. 2007).
A number of pre-clinical studies have evaluated the
physiological consequences of long-term Δ9-THC treat-
ment (usually 5–10 days) on CB1 receptors. These studies
have provided evidence that the pharmacological toler-
ance developed after chronic exposure to cannabis or can-
nabinoid receptor agonists results in adaptations of CB1
receptor density (i.e. downregulation and desensitization)
(Maldonado 2002; Gonzalez, Cebeira & Fernandez-Ruiz
2005; Clapper, Mangieri & Piomelli 2009) and their
downstreamcellular effectors (for a review, seeHoffman&
Lupica 2013). Decreased CB1 receptor levels as well as
impaired G-protein receptor coupling have been reported
in animals made tolerant to the behavioural effects of
cannabinoids (Oviedo, Glowa & Herkenham 1993;
Rodriguez de Fonseca et al. 1994; Sim et al. 1996;Romero
et al. 1998; Breivogel et al. 1999; Sim-Selley & Martin
2002). Additional studies have suggested that dysre-
gulated protein phosphorylation downstream of the
CB1 receptor may also contribute to the development of
tolerance (Martin, Sim-Selley & Selley 2004). However,
the exact role of the CB1 receptor in the development of
dependence and tolerance in humans is still poorly under-
stood. In vivo changes in CB1 receptor availability have
been previously described in alcoholic patients (Ceccarini
et al. 2009;Hirvonen et al. 2012b). Recently,wehave pro-
vided pre-clinical evidence that chronic ethanol expo-
sure leads to decreased CB1 receptor availability in several
areas such as caudate-putamen, hippocampus, and
insular and primary sensory cortices (Ceccarini et al.
2013a).
Regarding cannabis addiction, a post-mortem investi-
gation of brains from chronic cannabis users found a
reduction in [3H]SR141716A binding and decreased CB1
receptor mRNA levels in the caudate nucleus, putamen,
nucleus accumbens and hippocampal cortex (Villares
2007). Concerning in vivo investigations, so far there is
only one positron emission tomography (PET) imaging
study that investigated CB1 receptor binding in daily
cannabis users, demonstrating a selective cortical
downregulation of CB1 receptors (Hirvonen et al. 2012a).
The aim of the present study was therefore to investigate
and replicate in vivo changes in CB1 receptor availability in
chronic cannabisusers andcannabis-naïve controlsusing
a selective high-affinity CB1 receptor PET radioligand
[18F]MK-9470.
MATERIALS AND METHODS
Participants
The study was approved by the local ethics committee
and was conducted in full accordance with the World
Medical Association Declaration of Helsinki. All partici-
pants provided written informed consent.
Ten chronic cannabis users (age: 26.0 ± 4.1 years)
with regular cannabis use (at least once a month for at
least 4 years) and 10 cannabis-naïve controls (age:
23.0 ± 2.9 years) were included in the imaging study
(Table 1). Cannabis users were recruited from coffee
shops in Maastricht (the Netherlands) or via word-of-
mouth advertising, and controls were recruited in
response to advertisements in the departmental home-
page and local community newspapers.
Controls were healthy according to their histories and
results of physical examinations, psychiatric screening
interviews and routine blood and urine analyses. Canna-
bis users and controls were excluded if they experienced a
history of any major somatic disease or severe mental
disorder [meeting DSM-IV criteria (American Psychiatry
Association2000) for psychotic disorder, bipolar disorder,
drug addiction disorder (including alcohol) or any other
mental disorder requiring treatment by mental health
services and/or use of psychotropic medications such as
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antidepressants, lithium or antipsychotics], severe head
trauma, a family history of psychotic or bipolar disorder
according to DSM-IV criteria, a recent history of alcohol
abuse (> 5 alcoholic units/day in the past 30 days) to
exclude any possible acute-term alcohol effect on CB1
receptor (Ceccarini et al. ‘Changes in cerebralCB1 receptor
availability after acute and chronic alcohol abuse and
monitored abstinence’ J. of Neurosci., in press) and use of
any illicit drugs other than cannabis (for cannabis users)
in the preceding 2 weeks. Moreover, cannabis users had
not experienced negative effects (i.e. cannabis-induced
psychosis or psychedelic crisis or bad trip) secondary
to cannabis use given the association between the
endocannabinoid system (hence the CB1 receptor) and
psychosis (Ceccarini et al. 2013b). Participants were
asked to abstain from alcohol for 48 hours before PET
imaging. Volunteers who were also current tobacco
cigarette smokers had a last smoke at least 6 hours
before PET.
In addition to the psychiatric evaluation, on the day of
PET scanning, blood pressure and heart rate were moni-
tored prior to the scanning sessions. Use of ampheta-
mine, barbiturates, benzodiazepines, cocaine, ecstasy,
methamphetamine, morphine, methadone, tricyclic anti-
depressants and cannabis was also tested prior to the
PET scan by urinalysis (MultiDip-Drug Control Screen,
Ultimed Products, Ahrensburg, Germany) to ensure that
they did not currently abuse drugs other than cannabis.
All investigations were evaluated by board-certified
specialists.
Image acquisition
Before scanning, all participants were interviewed
by a psychiatrist who recorded drug and cannabis
consumption parameters (frequency, dose, age of first
use) using the Composite International Diagnostic
Interview (CIDI, v 1.1) (World Health Organization
1993).
All participants underwent [18F]MK-9470 PET scans.
The radiotracer [18F]MK-9470 is an inverse agonist with
a high affinity and specificity for the human CB1 receptor
(Burns et al. 2007). [18F]MK-9470 was prepared as
previously described (Burns et al. 2007) and had a
radiochemical purity > 95 percent and a specific radioac-
tivity of 150.4 ± 61.5 GBq/μmol.
Cannabis users did not smoke cannabis for 4.0 ± 1.7
days prior to the scanning session to avoid confounding
by acute intoxication. All subjects fasted for at least 4
hours prior to the injection of the radioligand to ensure
that cerebral radioligand uptake is not influenced by
increased serum glucose levels. Before each [18F]MK-
9470 administration, subjects were placed with the
head placed in a vacuum cushion and the body fixed to
minimize head movement. PET data were acquired on
a HiRez Biograph 16-slice PET/CT camera (Siemens,
Knoxville, TN, USA). Subjects received 146.8 ± 6.7 MBq
of [18F]MK-9470 in slow bolus intravenous injection.
Images were acquired for 60 minutes (six 10-minute
frames) starting 120 minutes post-injection. PET images
were reconstructed with 3D-OSEM (ordered-subset
expectation maximization) iterative reconstruction
including scatter and attenuation correction with a final
spatial resolution of 4 mm. Additionally, structural brain
abnormalities were evaluated by a standard magnetic
resonance imaging (MRI) scan (1.5 Tesla Vision Scanner,
Siemens, Germany), both T1-weighted magnetization
prepared rapid acquisition gradient echo (3D-MPRAGE)
and T2 weighted.
Image processing and statistical analysis
Parametric maps of [18F]MK-9470 binding were ex-
pressed on the basis of previously validated quantification
Table 1 Demographic characteristics for
cannabis users and controls. Cannabis users Controls P
Gender, male/female 8/2 7/3 > 0.99
Age, years 26.0 ± 4.1 23.0 ± 2.9 0.07
BMI 22.4 ± 2.7 22.9 ± 3.5 0.91
Injected activity of [18F]MK-9470, MBq 145.7 ± 7.4 148.2 ± 5.8 0.44
Age of onset of cannabis use, years 15.8 ± 2.5 — —
Duration of cannabis use, years 10.2 ± 4.6 — —
Amount of cannabis, joints per day 2.7 ± 2.4 — —
Frequency of cannabis usea heavy/
moderate/low, n
6/3/1 —
Tobacco smokers/non-smokers, n 6/4 0/10 0.03
Number of alcoholic units/day 1.8 ± 1.5 0.9 ± 0.5 0.08
aFrequency of cannabis use in the last 12 months assessed by Composite International Diagnostic
Interview (CIDI), categorized into ‘heavy use’ (several times a day), ‘moderate use’ (from once a day
to three to four times a week) and ‘low use’ (from two to three times a month or less). BMI = body
mass index. Data represent mean ± standard deviation.
CB1 receptor in cannabis users 359
© 2013 Society for the Study of Addiction Addiction Biology, 20, 357–367
method using the modified standardized uptake value
(mSUV) (Sanabria-Bohorquez et al. 2010; Van Laere et al.
2010, 2012; Gérard et al. 2011; Ceccarini et al. 2013b).
The mSUV index has been shown to be an index for
[18F]MK-9470 binding, and was shown to be strongly
independent of blood flow (Sanabria-Bohorquez et al.
2010). mSUV quantification normalizes radioactivity
concentration at each voxel with injected radioactivity
dose and subject’s weight: mSUV = [activity concentra-
tion (KBq/cc) × (subject’s body weight (kg) + 70)/2]/in-
jected dose (MBq) (Thie et al. 2007). No differences in
[18F]MK-9470 plasma concentration and metabolization
were found between a subgroup (n = 4) of cannabis users
that underwent full arterial sampling and controls (see
Supporting Information Fig. S1). Therefore, we excluded
possible group differences in peripheral metabolism or
metabolite-corrected plasma activity input functions that
could lead to bias in CB1 receptor availability determina-
tion by the simplified quantification.
The PET data analysis was performed with PMOD
v. 2.95 (PMOD Technologies, Zurich, Switzerland) as
in our previous CB1 receptor studies (Van Laere et al.
2008, 2009, 2010, 2012; Gérard et al. 2011; Ceccarini
et al. 2013b). For each subject, all PET frames were
first realigned for motion correction. The motion-
corrected [18F]MK-9470 mSUV individual images were
co-registered (rigid body transformation) to the corre-
sponding subject’s MRI with a mutual information algo-
rithm, and were then spatially normalized to a specific
CB1 receptor template (Van Laere et al. 2008) constructed
in Montreal Neurological Institute space (2 × 2 × 2 mm)
using non-linear warping. A predefined volume-of-
interest (VOI) analysis was performed using an in-house
previously created set of VOIs defined on the CB1 receptor
template representing cortical Brodmann areas (BAs)
and subcortical grey matter structures (Van Laere et al.
2006). Additionally, individual adjustments were made
for the subcortical brain areas by delineating these
regions manually on the transverse slices of the normal-
ized MRI images. The personalized VOI map was then
loaded on the corresponding co-registered and normal-
ized mSUV image, and the average mSUV values within
each VOI were then determined using PMOD. mSUV
values of cortical BAs were then grouped into larger
anatomical brain regions on the base of the number of
voxels, and compared between cannabis users and con-
trols using ANOVA and Bonferroni post hoc tests
(P < 0.05), by use of Statistica v. 9.1 (Statsoft Inc., Tulsa,
OK, USA).
A voxel-based statistical parametric analysis (SPM2;
Wellcome Department of Cognitive Neuroscience,
London, England) was also conducted comparing canna-
bis users and controls in a categorical subject design.
Data were first smoothed with a 10-mm full width at half
maximum. For statistical assessment of CB1 receptor
availability, non-proportional scaling was used and a
relative grey matter analysis threshold of 80 percent of
the mean was adopted to exclude extracerebral activity.
We also investigated relative CB1 receptor availability by
normalization to the global cerebralmSUV. For analysis of
relative CB1 receptor availability, proportional scaling to
the mean voxel value was used. Data were then explored
at a voxel-level Pheight = 0.005 (uncorrected) and extent
threshold Kext > 50 voxels, unless specified otherwise. To
exclude the influence of tobacco smoking as confounder,
statistical parametric mapping (SPM) analyses were done
with and without this parameter as nuisance variable.
RESULTS
Participants
Demographic characteristics of cannabis users and con-
trols are shown in Table 1. There were no differences
between the two groups in sex, age, body mass index,
injected activity of [18F]MK-9470 and alcohol consump-
tion. Overall, 60 percent of the cannabis users also con-
sumed tobacco.
Table 1 also shows the characteristics of cannabis
consumption. Almost all cannabis users had used canna-
bis on a daily basis, starting from adolescence. The age at
first cannabis use was 15.8 ± 2.5 years and the duration
of cannabis use was 10.2 ± 4.6 years. For the cannabis
consumption, all participants had used cannabis for at
least 4 years prior to screening. The frequency of lifetime
cannabis use was categorized into ‘heavy use’ (several
times a day; n = 6), ‘moderate use’ (from once a day to
three to four times a week; n = 3) and ‘low use’ (from two
to three times a month or less; n = 1), according to the
CIDI (Table 1). Although urine screening for canna-
binoids was not positive for all cannabis users (positive for
80 percent), urine cannabinoid results did not have any
effect on the change of the CB1 receptor availability
between cannabis users and controls (F = 1.39, P = 0.27;
Supporting Information Fig. S2).
None of the controls had lifetime use of cannabis or
any other illicit substance. The number of chronic can-
nabis users who had used other illicit drugs between 10
and 99 times in their lifetime was low; the great majority
of cannabis users (70 percent) were sporadic users (few
times per year) of other drugs (including amphetamine,
cocaine, ecstasy and opiates). Furthermore, no cannabis
user had consumed other drugs in the past 15 days, as
confirmed by blood and urine testing.
CB1 receptor group comparisons
Compared with controls, there was a global decrease of
CB1 receptor availability (−11.7 percent) in the cannabis
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group (mSUVCANNABIS = 1.21 ± 0.09, mSUVCONTROLS =
1.37 ± 0.24; P = 0.06) (Fig. 1). Regional VOI-based
analysis demonstrated that the CB1 receptor decrease
was significant in the temporal lobe (−12.7 percent,
P = 0.04), anterior and posterior cingulate cortex (for
aCC: −12.6 percent, P = 0.04; for pCC: −13.5 percent;
P = 0.04) and nucleus accumbens (−11.2 percent,
P = 0.04) (Fig. 2 and Table 2), while there was a trend in
occipital lobe (−12.8 percent; P = 0.05), frontal lobe
(−12.2 percent; P = 0.06), central lobe (−11.6 percent;
P = 0.06), insula (−11.5 percent; P = 0.05) and parietal
lobe (−11.7 percent; P = 0.08) (Table 2). In contrast, we
did not find decreased CB1 receptor levels in subcortical
brain regions such as mesotemporal lobe, thalamus,
putamen, globus pallidum, caudate nucleus, cerebellum
and pons (P ≥ 0.10) (Table 2).
Absolute SPM voxel-based analysis confirmed this
bilateral decrease and regional pattern in CB1 receptor
Figure 1 Average modified standardized uptake value (mSUV) parametric images of global CB1 receptor availability for controls and cannabis
users.The colour bar indicates [18F]MK-9470 binding (mSUV) index
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Figure 2 Regional differences in CB1 receptor (CB1R) availability between controls and cannabis users. Error bars represent one SD.
aCC = anterior cingulate cortex; CBL = cerebellum; Cent = central area; CN = caudate nucleus; Front = frontal cortex; Mesot = mesotemporal
lobe; NuAc = nucleus accumbens; Occ = cccipital cortex; Pal = globus pallidus; Par = parietal cortex; pCC = posterior cingulate cortex;
Put = putamen;Temp = temporal cortex;Thal = thalamus. *P < 0.05 ANOVA and Bonferroni post hoc tests
CB1 receptor in cannabis users 361
© 2013 Society for the Study of Addiction Addiction Biology, 20, 357–367
availability in chronic cannabis users (Fig. 3), with a
maximum t-value of 3.7 at (x = 48; y = −48; z = 24) in a
cluster including superior temporal gyri (BAs 41/39;
cluster size Kext = 322]. Relative voxel-based comparison
of [18F]MK-9470 binding in cannabis users versus con-
trols revealed a significant decrease in CB1 receptor avail-
ability in six clusters (t-value > 3.2) with a maximum
t-value of 5.1 at (x = −4; y = −76; z = 0; left BA 17), a
cluster including occipital regions (cluster size Kext = 447,
cluster-level Pcorrected = 0.028). The other five clusters
were located at the left insula (x = 42; y = −4; z = −4;
t = 4.8), right middle-posterior cingulum (x = 4; y = −44;
z = 40; t = 4.4), right inferior temporal gyrus (x = 64;
y = −22; z = −20; t = 4.2), left superior temporal gyrus
(x = −52; y = −4; z = −6; t = 4.1) and right superior
frontal gyrus (x = 26; y = −4; z = 62; t = 4.1).
These findingswere independent of tobacco consump-
tion. Cannabis userswhoalso smoke tobaccodidnot show
different CB1 receptor availability from non-smoking
cannabis users in all cerebral regions analysed (P >
0.05) (Supporting Information Table S1). SPM results
remainedwhen analysiswith current tobacco smoking as
nuisance variables was done. Moreover, repeated meas-
ures ANOVA did not show a main effect of tobacco
smoking (F = 0.66, P = 0.42) or a tobacco smoking per
VOI interaction (F = 0.84, P = 0.62) on mSUV among
cannabis users. This suggests that tobacco smoking did
not have a significant effect on CB1 receptor availability as
previously demonstrated in animal studies (Gérard et al.
2010).
Correlation between CB1 receptor availability and
cannabis consumption
In the cannabis users group, there were no associations
between CB1 receptor availability and the duration of
cannabis use or age of onset of cannabis use. We also
searched for correlations between CB1 receptor availabil-
ity and the level of cannabis consumption categorized
into low, moderate and heavy use. Yet, level of cannabis
consumption did not influence CB1 receptor availability
observed in cannabis users compared with controls
(F = 1.29, P = 0.33; Supporting Information Fig. S3).
However, although we found no significant correla-
tion between CB1 receptor availability and frequency of
Table 2 Regional CB1 receptor availability (mSUV) for cannabis
users versus controls.
Cannabis users Controls P
Frontal 1.24 ± 0.09 1.41 ± 0.26 0.06
Temporal 1.25 ± 0.09 1.43 ± 0.25 0.04*
Mesotemporal 1.04 ± 0.07 1.15 ± 0.20 0.10
Parietal 1.25 ± 0.01 1.42 ± 0.26 0.08
Occipital 1.23 ± 0.01 1.42 ± 0.26 0.05
Central 1.19 ± 0.08 1.34 ± 0.23 0.06
Insula 1.20 ± 0.08 1.36 ± 0.22 0.05
aCC 1.34 ± 0.10 1.53 ± 0.27 0.04*
pCC 1.35 ± 0.12 1.56 ± 0.27 0.04*
Putamen 1.44 ± 0.14 1.60 ± 0.25 0.10
Globus pallidus 1.22 ± 0.10 1.35 ± 0.22 0.12
Caudate nucleus 1.23 ± 0.08 1.42 ± 0.20 0.13
Nucleus accumbens 1.11 ± 0.11 1.22 ± 0.21 0.04*
Thalamus 0.91 ± 0.08 1.00 ± 0.18 0.17
Pons 0.79 ± 0.05 0.86 ± 0.13 0.11
Cerebellum 1.14 ± 0.10 1.25 ± 0.20 0.16
*Significant at P < 0.05 (ANOVA with Bonferroni post hoc correction
testing). aCC = anterior cingulate cortex; mSUV = modified standardized
uptake value; pCC = posterior cingulate cortex. Data represent mean ±
standard deviation.
Figure 3 Statistical parametric mapping (SPM) results of the absolute decrease in CB1 receptor availability in chronic cannabis users
compared with controls in transverse, coronal and sagittal sections overlaid on a T1-weighted magnetic resonance imaging template
(Pheight < 0.005 uncorrected, Kext > 50).The colour bar expresses t-score levels
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lifetime cannabis use, low cannabis consumption did not
produce similar CB1 receptor downregulation: the subject
with the lowest cannabis use showed the smallest global
CB1 receptor decrease (−5.8 percent) compared with can-
nabis users with a moderate and/or heavy use (−15.8
percent).
DISCUSSION
Pre-clinical, pharmacological and epidemiological evi-
dence has implicated the CB1 receptor in regulating
several Δ9-THC-induced behavioural effects such as
reward, subjective effects and the positive- and negative-
reinforcing cannabis effects (Cooper & Haney 2008).
However, although the exact role of the CB1 receptor in
the development of dependence and tolerance in humans
is still poorly understood, the CB1 receptor has been sug-
gested as a target for treatment of cannabis dependence
(Cooper & Haney 2008; Clapper et al. 2009). So far, only
one recent PET study has investigated CB1 receptor avail-
ability in chronic cannabis users (Hirvonen et al. 2012a).
In the present study, we make first use of the selective
high-affinity PET radioligand [18F]MK-9470 to investi-
gate in vivo measurements of cerebral CB1 receptor avail-
ability in chronic cannabis users compared with control
subjects, and to correlate CB1 receptor changes with
cannabis consumption.
Overall, we found a reduction in CB1 receptor availabil-
ity in chronic cannabis users compared with cannabis-
naïve controls. The decrease in CB1 receptor availability
was significant in the temporal lobe, nucleus accumbens,
and anterior and posterior cingulate cortex, and close
to significance in several other areas of neocortex as
occipital lobe (P = 0.05), central lobe (P = 0.06), insula
(P = 0.05), frontal lobe (P = 0.06) or parietal lobe
(P = 0.08). However, we did not find decreased CB1
receptor levels in subcortical brain regions such as
mesotemporal lobe, thalamus, putamen, globus pallidum,
caudate nucleus, cerebellum or pons (P ≥ 0.10). Our
results are thus in line with the previous finding of lower
[18F]FMPEP-d2uptake in chronic cannabis smokers in cor-
tical regions, but not in subcortical brain regions as
caudate nucleus, midbrain, thalamus or pons (Hirvonen
et al. 2012a).
Regional CB1 receptor downregulation has been
demonstrated by both experimental and human studies.
With the exception of the nucleus accumbens, no rel-
evant decrease in CB1 receptor availability was found
in the basal nuclei, in the midbrain and in cerebellum.
Rodent studies have shown that long-term cannabinoid
administration produces an attenuation of both CB1
receptor availability (downregulation) and CB1-receptor-
agonist-stimulated G-protein activation (desensitiza-
tion), which are believed to contribute to tolerance to
cannabinoid-mediated effects (Romero et al. 1997;
Breivogel et al. 1999, 2003; Sim-Selley & Martin 2002;
Martin et al. 2004). Decreased CB1 receptor availability
and receptor-mediated G-protein activation have been
measured consistently using CB1 receptor binding in
brain sections or membrane homogenates from animals
treated with Δ9-THC, CP55940 or WIN552122, and
occurred throughout all CB1 receptor-containing brain
regions (Sim et al. 1996; Romero et al. 1997; Sim-Selley
& Martin 2002). However, the magnitude of down-
regulation varies, with a smaller change observed in the
basal ganglia output nuclei: globus pallidus, entopedun-
cular nucleus and substantia nigra. The finding of a close
regional and temporal correlation between decreases in
CB1 receptor availability sites and decreases in G-protein
activation (Breivogel et al. 1999; Sim-Selley & Martin
2002) suggests that these two adaptive responses share
a common mechanism, such as internalization and
degradation of CB1 receptor.
However, the mechanism by which long-term can-
nabinoid administration attenuates CB1 receptor func-
tion in the brain has not yet been resolved. The observed
decreased CB1 receptor availability may also be the con-
sequence of other molecular mechanisms such as cross-
desensitization, allosteric modulation, disruption in CB1
receptor dimerization and trafficking. By analogy with
cultured cell models, the mechanisms of CB1 receptor
desensitization and downregulation might include G-
protein coupled receptor kinase-mediated phosphoryla-
tion and association of the receptor with β-arrestin,
although this remains to be established in the central
nervous system. Changes in expression of the gene
encoding the CB1 receptor might also play a role in some
brain regions, but not others. Another cellular conse-
quence of chronic cannabinoid administration is a com-
pensatory increase in cyclic adenosine monophosphate
synthesis with concomitant enhancement of protein
kinase A activity (Martin et al. 2004). However, from the
current findings, it remains unclear whether changes in
receptor availability are due to altered receptor density, or
changes in receptor affinity or in receptor trafficking, as
these mechanisms cannot be distinguished with PET.
However, previous studies demonstrated significant CB1
receptor downregulation as a result of loss of CB1 recep-
tor protein after chronic agonist exposure (Sim-Selley
2003; Sim-Selley et al. 2006), suggesting a change in
receptor density rather than affinity. Nevertheless, the
decreased CB1 receptor availability cannot be due to a
possible competition effect of Δ9-THC with the [18F]MK-
9470 radioligand. Firstly, Δ9-THC acts non-selectively as
partial agonist at both cannabinoid CB1 and CB2 receptors
(Pertwee et al. 2010), whereas the CB1 receptor subtype
selectivity of [18F]MK-9470 is about 60-fold over CB2
receptors (Burns et al. 2007). Secondly, the affinity of
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Δ9-THC is similar to that of the endocannabinoid
anandamide (Pertwee et al. 2010). Comparing the affin-
ity of the endocannabinoids (26–209 nM for AEA and
even above 10 μM for 2-AG) to the nanomolar affinity of
[18F]MK-9470 (0.7 nM) for the human CB1 receptor, it is
rather unlikely that Δ9-THC competes with the
radioligand [18F]MK-9470 for binding to the CB1 receptor.
To look at the status of a receptor without any influence
from the endogenous or exogenous ligand, high-affinity
radioligands are necessary, as is the case with [18F]MK-
9470. Furthermore, as demonstrated previously for
[11C]MePPEP, a CB1 receptor radioligand with a similar
affinity, current high-affinity CB1 receptor radioligands
are not displaceable in vivo by high doses of endogenous
agonist or synthetic agonists (Terry et al. 2008).
Animal and human studies furthermore reported that
decreased CB1 receptor availability recovered after canna-
bis abstinence of at least a few weeks (Sim-Selley et al.
2006; Hirvonen et al. 2012a). Considering the similar
demographic and cannabis history characteristics of the
cannabis users group analysed in the current study with
the one investigated by Hirvonen et al. (2012a), and con-
sidering that after 4 weeks of continuously monitored
abstinence from cannabis CB1 receptor density returned
to normal levels (Hirvonen et al. 2012a), decreased CB1
receptor binding may thus reflect a state condition rather
than an enduring trait-like feature. However, longer
follow-up is necessary to differentiate this.
Interestingly, our findings confirm that chronic can-
nabis consumption decreases CB1 receptor availability in
cortical regions but also in the nucleus accumbens, a key
structure for reward and drug reinforcement (van der
Stelt & Di Marzo 2003). The brain circuitry that is shared
between cue-, drug- and stress-primed reinstatement
converges on the anterior cingulate cortex and has a
final common output through the nucleus accumbens
(Kalivas & McFarland 2003). Moreover, it has been
reported that glutamatergic projections from the
prefrontal areas to the nucleus accumbens play an impor-
tant role in relapse behaviour (Kalivas & McFarland
2003). Nucleus accumbens has been also identified as
one of the two brain trigger zones for stimulant and
rewarding effects of Δ9-THC, together with the ventral
tegmental area (VTA) (Zangen et al. 2006). Briefly,
microinjections of Δ9-THC into the posterior VTA or into
the shell of the nucleus accumbens increased locomo-
tion, and rats learned to lever press for injections of
Δ9-THC into each of these regions, an effect that is
blocked by SR141716A (Zangen et al. 2006). Moreover,
repeated exposure to Δ9-THC resulted in tolerance to the
inhibitory effects of WIN55,212-2 in the nucleus
accumbens, and the tolerance was associated with a loss
of endocannabinoid-mediated long-term depression
(Hoffman et al. 2003). It seems that either short-term or
long-term exposure to Δ9-THC can limit the degree to
which nucleus accumbens glutamate synapses undergo
long-term depression, and this appears to result from a
downregulation of CB1 receptor function and the ability
of endocannabinoids to initiate this form of synaptic plas-
ticity (Hoffman & Lupica 2013). This effect of Δ9-THC
may altermotivational processesmediated by the nucleus
accumbens and may play a role in modulating the rein-
forcing properties of other abused drugs acting either
directly within the nucleus accumbens or indirectly by
altering dopamine function in this brain structure
(Hoffman & Lupica 2013).
Notably, our findings did not show any correlations
between CB1 receptor availability and age at onset of
smoking, number of joints per day or duration of canna-
bis use. One possible reason could be the small variance in
these variables for the current population that might
have obscured some of the possible correlations.
However, the subject with lowest cannabis use showed
the smallest global CB1 receptor decrease (−5.8 percent)
compared with the cannabis users with moderate or
heavy use (−15.8 percent; Supporting Information
Fig. S3). This is in line with Hirvonen and colleagues,
who reported that the cannabis users who, on average,
smoked three joints per day showed a smaller global
CB1 receptor decrease (∼12 percent) in comparison with
cannabis users who smoked 10 joints per day on average
(∼20 percent) (Hirvonen et al. 2012a). This latter study
furthermore revealed a relationship between decreased
CB1 receptor density and years of cannabis smoking. Con-
sidering that subjects who occasionally smoke cannabis
do not develop tolerance to the level that heavy chronic
daily smokers do (Cooper & Haney 2008), and that occa-
sional cannabis users likely differ in terms of CB1 receptor
downregulation, we could therefore assume that CB1
receptor downregulation contributes to the development
of tolerance of cannabis. Further studies need to address
this issue by comparing CB1 receptor availability in heavy,
moderate and occasional cannabis smoking.
Our findings should be interpreted considering
some potential limitations. Firstly, cannabis users were
scanned on average after 5 days of cannabis abstinence to
avoid acute intoxication. This is different from Hirvonen
et al. (2012a) where cannabis smokers were imaged on
the day following the last cannabis consumption tomaxi-
mize the effect size of the hypothesized CB1 receptor
downregulation. Thus, a potential abstinence effect due
to short-term deprivation of cannabis cannot be fully
excluded. However, as results are very similar to
Hirvonen et al., such effect seems to be modest at most.
Secondly, for quantification of CB1 receptor availability,
the simplified mSUV measure was used. Modelling of
tracer kinetics indicated that the use of mSUV as quanti-
fication measure is an index of CB1 receptor availability
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related to distribution volume VT (Sanabria-Bohorquez
et al. 2010). Moreover, it has been recently demonstrated
that this approach allows a more practical acquisition
protocol in patients and is a valid simplified quantification
providing an index of tracer binding, given that no group
differences in peripheral metabolization are present (Van
Laere et al. 2010, 2012; Gérard et al. 2011; Ceccarini
et al. 2013b). The latter was also explicitly demonstrated
for the subjects in this study. Finally, because of the small
sample size limited to 10 cannabis users, the decreased
CB1 receptor availability found in the current study
awaits independent replications in larger samples.
However, considering the similarity between the current
findings with the ones obtained with 30 cannabis users
(Hirvonen et al. 2012a), we think that, overall, our main
conclusions should be considered well founded rather
than preliminary.
In conclusion, the results presented here provide
further in vivo evidence that chronic cannabis use pro-
duces regional downregulation of CB1 receptors. Future
studies should focus on longitudinal CB1 receptor evalu-
ation after episodes of cannabis deprivation in order
to understand the state versus trait differences that
might open the way for the examination of specific CB1-
cannabis addiction interactions, which may predict
future cannabis-related treatment outcome. Regarding
the current pharmacological treatments of cannabis
dependence, a range of medications have been tested in a
human laboratory model of cannabis dependence as oral
Δ9-THC, divalproex, bupropion, nefazodone, buspirone,
dronabinol and naltrexone (Weinstein & Gorelick 2011).
Abstinence in cannabinoid-dependent subjects elicits
withdrawal symptoms that promote relapse into drug
use, suggesting that pharmacological strategies aimed at
alleviating cannabis withdrawal might prevent relapse
and reduce dependence (Clapper et al. 2009). However,
there are currently no medications approved by any
national regulatory authority to treat cannabis-related
disorders. The only treatment currently shown consist-
ently to alleviate cannabinoid withdrawal in both ani-
mals and humans is substitution therapy using oral
Δ9-THC (Weinstein & Gorelick 2011). However, new
genetic and pharmacological tools are available to
increase endocannabinoid levels by targeting fatty acid
amide hydrolase (FAAH) or monoacylglycerol lipase
(MAGL), the enzymes responsible for the degradation of
the endogenous cannabinoid ligands anandamide and
2-arachidonoylglycerol, respectively. In line with this
consideration, a pre-clinical study has shown that
acute administration of either FAAH inhibitor URB597
or MAGL inhibitor JZL184 significantly attenuated
rimonabant-precipitated withdrawal signs in Δ9-THC-
dependent mice (Schlosburg et al. 2009), supporting
the concept of targeting endocannabinoid-metabolizing
enzymes as a promising treatment for cannabis
withdrawal.
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